

FORM PTO-1449 (modified)  
To: U.S. Department of Commerce  
(PW FORM PAT-1449)  
Patent and Trademark Office

Atty.  
Dkt. No.

M#

Client Ref.

037003-0275470

1997-30-0565CP1

**INFORMATION DISCLOSURE STATEMENT  
BY APPLICANT**

Applicant: Mitchell E. REFF et al.

Appln. No.: 09/019,441

Filing Date: February 5, 1998

Examiner: P. Huynh

Group Art Unit: 1644

Date: January 15, 2004

Page

1

of

1

**U.S. PATENT DOCUMENTS**

Examiner's Initials*	Document Number	Date MM/YYYY	Name (Family Name of First Inventor)	Class	Sub Class	Filing Date (if appropriate)
Pst	AR 6,001,358	12/1999	Black et al.	424	154.1	
Pst	BR 6,136,310	10/2000	Hanna et al.	424	154.1	
CR						

**FOREIGN PATENT DOCUMENTS**

	Document Number	Date MM/YYYY	Country	Inventor Name	English Abstract		Translation Readily Available	
					Enclosed	No	Enclose	No
	DR							
	ER							
	FR							
	GR							
	HR							

**OTHER (Including in this order Author, Title, Periodical Name, Date, Pertinent Pages, etc.)**

Pst	IR	Boulet et al., "Inhibitory Effects of an Anti-IgE Antibody E25 on Allergen-induced Early Asthmatic Response," <i>Am J Respir Crit Care Med</i> , (1997) 155:1835-44.
	JR	Casale et al., "Use of an anti-IgE humanized monoclonal antibody in ragweed-induced allergic rhinitis," <i>J Allergy Clin Immunol</i> , (1997), 100:110-120.
	KR	Coyle et al., "Central Role of Immunoglobulin (Ig) E in the Induction of Lung Eosinophil Infiltration and T Helper 2 Cell Cytokine Production: Inhibition by a Non-anaphylactogenic Anti-IgE Antibody," <i>J Exp Med</i> , (1996), 183:1303-1310.
	LR	Fahy et al., "The Effect of an Anti-IgE Monoclonal Antibody on the Early-and Late-Phase Responses to Allergen Inhalation in Asthmatic Subjects," <i>Am J Respir Crit Care Med</i> , (1997), 155:1828-34.
	MR	Ohashi et al., "Immunotherapy Affects the Seasonal Increase in Specific IgE and Interleukin-4 in Serum of Patients with Seasonal Allergic Rhinitis," <i>Scan J Immunol</i> , (1997), 46(1):67-77.
	NR	Ohashi et al., "Serum levels of specific IgE, soluble interleukin-2 receptor, and soluble intercellular adhesion molecule-1 in seasonal allergic rhinitis," <i>Annals of Allergy, Asthma, and Immunol</i> , (1997), 79:213-220.
	OR	Ohashi et al., "Ten-Year Follow-Up Study of Allergen-Specific Immunoglobulin E and Immunoglobulin G4, Soluble Interleukin-2 Receptor, Interleukin-4, Soluble Intercellular Adhesion Molecule-1 and Soluble Vascular Cell Adhesion Molecule-1 in Serum of Patients on Immunotherapy for Perennial Allergic Rhinitis," <i>Scand J Immunol</i> , (1998), 47:167-178.
	PR	Peebles et al., "Ragweed-specific antibodies in bronchoalveolar lavage fluids and serum before and after segmental lung challenge: IgE and IgA associated with eosinophil degranulation," <i>J Allergy Clin Immunol</i> , (1998), 101:265-273.
	QR	Pullerits et al., "An intranasal glucocorticoid inhibits the increase of specific IgE initiated during birch pollen season," <i>J Allergy Clin Immunol</i> , (1997), 100:601-605.
✓	RR	Ward E.S. and Ghetie V., "The effector functions of immunoglobulins: implications for therapy," 1995, <i>Therapeutic Immunology</i> , 2:77-94.

Examiner

Date Considered:

\*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.